CN106266341A - A kind of Chinese medicine composition treating gout - Google Patents
A kind of Chinese medicine composition treating gout Download PDFInfo
- Publication number
- CN106266341A CN106266341A CN201610748422.6A CN201610748422A CN106266341A CN 106266341 A CN106266341 A CN 106266341A CN 201610748422 A CN201610748422 A CN 201610748422A CN 106266341 A CN106266341 A CN 106266341A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- preparation
- gout
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 40
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 201000005569 Gout Diseases 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 13
- 239000008187 granular material Substances 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 240000008669 Hedera helix Species 0.000 claims abstract description 12
- 210000000582 semen Anatomy 0.000 claims abstract description 12
- 206010003549 asthenia Diseases 0.000 claims abstract description 11
- 230000003393 splenic effect Effects 0.000 claims abstract description 11
- 239000007788 liquid Substances 0.000 claims abstract description 7
- 239000002775 capsule Substances 0.000 claims abstract description 4
- 239000002552 dosage form Substances 0.000 claims abstract description 3
- 239000003937 drug carrier Substances 0.000 claims abstract description 3
- 239000006187 pill Substances 0.000 claims abstract description 3
- 239000003826 tablet Substances 0.000 claims abstract description 3
- 244000046052 Phaseolus vulgaris Species 0.000 claims 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 210000000952 spleen Anatomy 0.000 description 15
- 208000002193 Pain Diseases 0.000 description 12
- 230000036407 pain Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 210000003734 kidney Anatomy 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000006820 Arthralgia Diseases 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 229940116269 uric acid Drugs 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 206010018634 Gouty Arthritis Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010043949 Tongue discolouration Diseases 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010062104 Renal mass Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010046337 Urate nephropathy Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical compound [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 1
- 208000010553 multiple abscesses Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229960003329 sulfinpyrazone Drugs 0.000 description 1
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a kind of Chinese medicine composition treating gout, it is characterised in that these Chinese medicine composition prescription parts by weight are calculated as: the Rhizoma Atractylodis Macrocephalae 10 50 parts, 10 50 parts of Poria, Caulis Trachelospermi 5 30 parts, Rhizoma Typhonii 5 30 parts, Cortex Cinnamomi 3 15 parts, Semen Lablab Album 3 20 parts.This Chinese medicinal composition preparation is made up of with pharmaceutically acceptable carrier Chinese medicine composition, and dosage form includes water decoction, pill, tablet, capsule, granule, electuary and oral liquid.The present composition is evident in efficacy for Splenic asthenia and obstruction of dampness patient with gout, has no side effect.
Description
Technical field
The invention belongs to field of traditional Chinese, be specifically related to a kind of Chinese medicine composition treating gout.
Background technology
Gout is that too much and kidney Scavenging activity declines, uric acid body accumulation due to internal generation uric acid, causes
Urate crystal deposits in joint and each internal organs.Along with the improving constantly of people's living standard, dietary structure and living habit
The change of (food rich in nucleoprotein increases), the prolongation of average life, the mankind are to the understanding of gout and carrying of diagnostic level
Height, either in American-European countries still in countries in Asia, the prevalence of gout has the trend increased year by year, and current China is high
Hyperuricemia patient numbers is more than 1.5 hundred million, and wherein patient with gout is more than 75,000,000 people, and increases with annual 0.97% annual rate of growth
Adding, gout has become China with the same second largest metabolism class disease of diabetes, and the life and health of people in serious threat.
Gout is belonging to the categories such as Chinese medical ' arthralgia syndrome ', due to spleen renal dysfunction, dysfunction of the spleen in transportation, causes endogenous damp formation；Kidney
The functional disorder of separating clear and excreting turbid, then turbid damp acatharsia, if indulging in excessive drinking the most again gluttony, overstrain etc., then promote turbid damp multiple abscess
In joint, muscle, cause QI-blood circulation smooth and form arthralgia pain, namely gouty arthritis.As the heresy of turbid damp hinder further in
Kidney then may result in renal damage, causes gouty nephropathy, even chronic kidney hypofunction.
Syndrome Differentiation of Traditional Chinese Medicine treats, and has good result.Can be divided into damp-heat arthralgia resistance type, disease sees redness and swelling of joints burning pain, and swelling is ached
Acutely, spasm of muscles and vessels, hands can not be near, it more difficult to out-of-bed activity, and day at light night is heavy, red tongue with yellow fur, slippery and rapid pulse for pain.Control suitable removing damp-heat,
Promoting blood circulation to remove obstruction in the collateral.Splenic asthenia and obstruction of dampness, disease sees that miserable heavy, the painful area in joint does not moves, joint deformity, stiff, has tophus, conscious
Breathing hard, indigestion and loss of appetite the most hungry, light red tongue tongue is the most greasy, soft pulse and count.Control suitable invigorating the spleen to clear away damp pathogen, let out turbid dredging collateral.Deficiency of the liver and kidney, disease sees gout
With the passing of time, arthroncus deformity, unable to flex and stretch the extremities, heavy then pain, soreness of the waist and knees, limb activity inconvenient, chance labor chance cold rnning weight, time have low
Heat, aversion to cold and preference for warmth, pale tongue with thin fur is white, and deep pulse is counted accurately or heavy the most unable.Control suitable liver and kidney tonifying, eliminating dampness and dredging channels.Cold-dampness numbness type, disease
Seeing limbs joint sharp ache, redness the most very, obtains hot, subtracts, joint joint stuffiness, and there is creeping chill local, and light red tongue tongue is white, stringy pulse
Tightly.Control suitable dispelling cold by warming the meridian, removing dampness of dispeling the wind.
Commonly using the current kind of antigout drug at present clinically few, clinical treatment mainly resists with colchicine, nonsteroidal
Scorching medicine, hormone, promotion urate excretion medicine (such as probenecid, sulfinpyrazone and benzbromarone) and suppression uric acid synthetic drug (allopurinol)
It is main.These medicines are the most defective in treatment；Weak curative effect, side effect become greatly the bottleneck of its clinical practice.
Summary of the invention
It is desirable to provide a kind of Chinese medicine composition treating gout.
For achieving the above object, a kind of Chinese medicine composition treating gout of the present invention, it the specific scheme is that
A kind of Chinese medicine composition treating gout of the present invention, it is characterised in that this Chinese medicine composition prescription parts by weight meter
For: Rhizoma Atractylodis Macrocephalae 10-50 part, Poria 10-50 part, Caulis Trachelospermi 5-30 part, Rhizoma Typhonii 5-30 part, Cortex Cinnamomi 3-15 part, Semen Lablab Album 3-20 part.
A kind of Chinese medicine composition treating gout of the present invention, it is characterised in that these Chinese medicine composition prescription parts by weight
It is calculated as: Rhizoma Atractylodis Macrocephalae 15-45 part, Poria 12-40 part, Caulis Trachelospermi 7-25 part, Rhizoma Typhonii 8-25 part, Cortex Cinnamomi 5-10 part, Semen Lablab Album 4-18
Part.
The Chinese medicine composition of a kind of gout of the present invention, it is characterised in that these Chinese medicine composition parts by weight are calculated as: white
Art 32 parts, 25 parts of Poria, Caulis Trachelospermi 20 parts, Rhizoma Typhonii 18 parts, Cortex Cinnamomi 8 parts, Semen Lablab Album 10 parts.
The preparation of Chinese medicine composition of the present invention, it is characterised in that described preparation is oral formulations.
Preparation of the present invention, it is characterised in that described preparation is by Chinese medicine composition and pharmaceutically acceptable carrier
Composition, dosage form includes water decoction, pill, tablet, capsule, granule, electuary and oral liquid.
Preparation of the present invention, it is characterised in that described preparation is granule.
The Chinese medicine composition of the present invention application in the Chinese medicine preparation of preparation treatment Splenic asthenia and obstruction of dampness gout.
Prescription of the present invention each component pharmacology analysis:
The Rhizoma Atractylodis Macrocephalae: nature and flavor are bitter, sweet, warm in nature；Return spleen, stomach warp；Invigorating the spleen and benefiting QI, dampness diuretic, hidroschesis, antiabortive；For insufficiency of the spleen lack of appetite, abdomen
Swollen have loose bowels, phlegm retention vertigo and palpitation, edema, spontaneous perspiration, frequent fetal movement.
Poria: property is sweet, light, flat；GUIXIN, spleen, lung meridian；Eliminating dampness and diuresis, invigorating the spleen and regulating the stomach, mind tranquilizing and the heart calming；For edema oliguria,
Phlegm retention vertigo and palpitation, insufficiency of the spleen lack of appetite, loose stool has loose bowels, irritability, palpitation with fear insomnia.
Caulis Trachelospermi: property is bitter, pungent, cold nature；Return liver, kidney channel；Removing obstruction in the collateral to relieve pain, heat clearing and blood cooling, removing toxic substances and promoting subsidence of swelling；For rheumatic fever
Numbness, muscle arteries and veins contracture, soreness of waist and knee joint, sore throat, carbuncle, injury from falling down.
Rhizoma Typhonii: property is pungent, temperature, poisonous；Return stomach, Liver Channel；Dispel the wind expectorant, the meridian dredging, removing toxic substances analgesia.
Cortex Cinnamomi: property is pungent sweet, heat；Return kidney, spleen, bladder warp；Mend fire supporing yang；Let the fire back to its origin；Dispersing cold for relieving pain；Warming the meridian and promoting blood circulation.With
In sexual impotence, cold womb, chills and pain of the waist and kness, suffer from a deficiency of the kidney and breathe heavily, dizziness due to yang deficiency, conjunctival congestion pharyngalgia, trusted subordinate's cold type of pain, deficiency and coldness vomiting and diarrhoea, colic of cold type, renal mass,
Amenorrhea, dysmenorrhea.
Semen Lablab Album: property is sweet, tepor；Return spleen, stomach warp；Spleen invigorating, removing dampness, relieve summer heat.For weakness of the spleen and stomach, inappetence, diarrhea,
Leukorrhagia, heat-damp in summer vomiting and diarrhoea, abdominal distention uncomfortable in chest.
The beneficial effects of the present invention is: employing natural materials is raw material, without additive, without hormone, scientific formula,
The Rhizoma Atractylodis Macrocephalae, Poria invigorating the spleen and benefiting QI, dampness diuretic；Caulis Trachelospermi, Rhizoma Typhonii removing obstruction in the collateral to relieve pain, heat clearing and blood cooling；Cortex Cinnamomi dispersing cold for relieving pain, warming the meridian
Promote blood circulation；Semen Lablab Album spleen invigorating, removing dampness, relieve summer heat；Cooperative compensating between each prescription, to treatment Splenic asthenia and obstruction of dampness gout good effect, nontoxic
Side effect.Add adjustment rule of life, strike a proper balance between work and rest, be careful in one's diet etc. and Splenic asthenia and obstruction of dampness gout can be reached treating both the principal and secondary aspects of a disease
Effect, it addition, the prescription crude drug source of the present invention is wide, technique is simple, is suitable for large-scale production, has industrialization prospect.
Detailed description of the invention
Example below, only for further illustrating the present invention, limits the scope of the invention the most in any form.
Embodiment 1
Present composition granule prescription and preparation method: take the Rhizoma Atractylodis Macrocephalae 32 parts, 25 parts of Poria, Caulis Trachelospermi 20 parts, Rhizoma Typhonii 18
Part, Cortex Cinnamomi 8 parts, Semen Lablab Album 10 parts, mixing, in crude drug, add the water of 8 times of quality, decoct 2 hours, filter；Medicinal residues add 6 times again
The water of quality, decocts 30 minutes, filters；Merge twice filtrate, concentrate the filtrate to solid-liquid ratio 1:2, after adding ethanol, regulate alcohol
Concentration stands 12-36 hour to 60-90%, dark place, filters, and reclaims ethanol, is concentrated into thick paste density 1.2-1.5(40-60 DEG C),
Dry, pulverize 80 mesh sieves, standby.Add the lactose of proper proportion, starch, dextrin stir, soft material processed.Cross 10 mesh
Sieve, obtains wet granular.50～60 DEG C are dried, and cross 10 mesh sieves and 65 mesh sieve granulate respectively, to obtain final product after the cooling of dry granule.Embodiment 2
Present composition granule prescription and preparation method: take the Rhizoma Atractylodis Macrocephalae 30 parts, 28 parts of Poria, Caulis Trachelospermi 25 parts, Rhizoma Typhonii 18
Part, Cortex Cinnamomi 8 parts, Semen Lablab Album 10 parts, mixing, in crude drug, add the water of 8 times of quality, decoct 2 hours, filter；Medicinal residues add 6 again
The water of times quality, decocts 30 minutes, filters；Merge twice filtrate, concentrate the filtrate to solid-liquid ratio 1:2, regulate after adding ethanol
Determining alcohol stands 12-36 hour to 60-90%, dark place, filters, and reclaims ethanol, is concentrated into thick paste density 1.2-1.5(40-60
DEG C), dry, pulverize 80 mesh sieves, standby.Add the lactose of proper proportion, starch, dextrin stir, soft material processed.Cross
10 mesh sieves, obtain wet granular.50～60 DEG C are dried, and cross 10 mesh sieves and 65 mesh sieve granulate respectively, to obtain final product after the cooling of dry granule.
Embodiment 3
Present composition capsule prescription and preparation method: take the Rhizoma Atractylodis Macrocephalae 34 parts, 25 parts of Poria, Caulis Trachelospermi 22 parts, Rhizoma Typhonii 18
Part, Cortex Cinnamomi 8 parts, Semen Lablab Album 10 parts, mixing, in crude drug, add the water of 8 times of quality, decoct 2 hours, filter；Medicinal residues add 6 times again
The water of quality, decocts 30 minutes, filters；Concentrating the filtrate to solid-liquid ratio 1:2, after adding ethanol, regulation determining alcohol is to 60-90%,
Dark place stands 12-36 hour, filters, and reclaims ethanol, is concentrated into thick paste density 1.2-1.5(40-60 DEG C), dry, pulverize 80
Mesh sieve, standby.Add the lactose of proper proportion, starch, dextrin stir, soft material processed.Cross 10 mesh sieves, obtain wet granular.50
～60 DEG C be dried, dry granule cooling after respectively cross 24 mesh sieve granulate, additional magnesium stearate, encapsulated, to obtain final product.
Embodiment 4
Present composition water decoction prescription and preparation method: take the Rhizoma Atractylodis Macrocephalae 36 parts, 25 parts of Poria, Caulis Trachelospermi 18 parts, Rhizoma Typhonii 22
Part, Cortex Cinnamomi 8 parts, Semen Lablab Album 10 parts, mixing, in crude drug, add the water of 8 times of quality, decoct 1.5 hours, filter；Medicinal residues add 5 again
The water of times quality, decocts 30 minutes, filters；Merge twice filtrate, make water decoction.
Embodiment 5
SPF rat Splenic asthenia and obstruction of dampness Gout Model is tested
Select 60 SPF level SD rat 200 ± 20g (male), after routine is raised 1 week under the conditions of SPF laboratory standard, divide at random
Become 6 groups, often group 10.1. blank group: feed normal diet+normal saline 9ml/kg gavage；2. model control group: feed common
Feedstuff+normal saline 9ml/kg gavage；3. the embodiment of the present invention 1,2,3,4 medication group: feed normal diet+finished product of the present invention water-soluble
Liquid (by the conversion metering of people Mus) gavage, concentration is 25.5g/kg body weight；In addition to blank group, all cause Splenic asthenia and obstruction of dampness pain
Wind model, after modeling success, successive administration 2 weeks, the results are shown in Table 1.
Modeling method: raise under relative humidity 95% environment 9 days, add and freely drink with 200 g/L hydromels, 1 g/
100 g quality ratios gavage oils and fats, inject 50 μ L Monosodium urate and manufacture Splenic asthenia and obstruction of dampness gouty model；
Table 1 present invention is to gouty arthritis pharmacodynamic results
Being seen by result, contrasting with model group, embodiment 1,2,3,4 administration group serum Uric Acid Concentration substantially reduces (P ＜ 0.05), joint
Zhou Jing is obviously reduced (P ＜ 0.05), illustrates that the embodiment of the present invention 1,2,3,4 can substantially reduce serum Uric Acid Concentration, its detumescence, improves
Joint function disturbance effect is preferable.
Embodiment 6
Splenic asthenia and obstruction of dampness, disease sees that miserable heavy, the painful area in joint does not moves, joint deformity, stiff, has a tophus, conscious breathes hard,
Indigestion and loss of appetite the most hungry, light red tongue tongue is the most greasy, soft pulse and count.
Therapeutic Method and judgment criteria:
Accept Splenic asthenia and obstruction of dampness patient with gout totally 250 example for medical treatment, in age 35-75 year, be randomly divided into 5 groups, often organize 50 people, placebo group,
Embodiment 1,2,3,4 groups；It within two weeks, it is a course for the treatment of.
Usage and dosage: embodiment 1: each 1 bag, three times a day；Embodiment 2: each 1 bag, three times a day；Embodiment 3: every time
2, three times a day；Embodiment 4: each 1 dose, three times a day；
Pass judgment on:
Effective: arthralgia disappears substantially, tongue fur is normal, and clinical symptoms disappears substantially;
Take a turn for the better: arthralgia alleviates, and red tongue white fur is thin out, and clinical symptoms substantially alleviates;
Invalid: arthralgia does not alleviates, red tongue white fur does not improves, and clinical symptoms is the most obvious;
Result is added up: all have no side effect after treating a course for the treatment of.
Wherein: total effective rate=obvious effective rate+improvement rate.
Seen by result, contrast with placebo group, embodiment 1,2,3,4 total effective rate the highest (P ＜ 0.05), this is described
Inventive embodiments 1,2,3,4 therapeutic effect is preferable.
Embodiment 6
The embodiment of the present invention 1 is carried out rat acetic acid induced pain experiment, and result shows: the medicine of the present invention has significantly analgesia
Effect.
The preferred embodiment of the present invention described in detail above.Should be appreciated that those of ordinary skill in the art without
Need creative work just can make many modifications and variations according to the design of the present invention.Therefore, all technology in the art
Personnel are available by logical analysis, reasoning, or a limited experiment the most on the basis of existing technology
Technical scheme, all should be in the protection domain being defined in the patent claims.
Claims (7)
1. the Chinese medicine composition treating gout, it is characterised in that these Chinese medicine composition prescription parts by weight are calculated as: Rhizoma Atractylodis Macrocephalae 10-
50 parts, Poria 10-50 part, Caulis Trachelospermi 5-30 part, Rhizoma Typhonii 5-30 part, Cortex Cinnamomi 3-15 part, Semen Lablab Album 3-20 part.
A kind of Chinese medicine composition treating gout, it is characterised in that this Chinese medicine composition prescription weight
Amount number is calculated as: Rhizoma Atractylodis Macrocephalae 15-45 part, Poria 12-40 part, Caulis Trachelospermi 7-25 part, Rhizoma Typhonii 8-25 part, Cortex Cinnamomi 5-10 part, the most flat
Bean 4-18 part.
The Chinese medicine composition of a kind of gout, it is characterised in that this Chinese medicine composition parts by weight meter
For: the Rhizoma Atractylodis Macrocephalae 32 parts, 25 parts of Poria, Caulis Trachelospermi 20 parts, Rhizoma Typhonii 18 parts, Cortex Cinnamomi 8 parts, Semen Lablab Album 10 parts.
4. according to the preparation of the Chinese medicine composition described in any one of claim 1-3, it is characterised in that described preparation is oral system
Agent.
Preparation the most according to claim 4, it is characterised in that described preparation by Chinese medicine composition with pharmaceutically acceptable
Carrier forms, and dosage form includes water decoction, pill, tablet, capsule, granule, electuary and oral liquid.
Preparation the most according to claim 5, it is characterised in that described preparation is granule.
7. the Chinese medicine composition described in any one of claim 1-6 is in the Chinese medicine preparation of preparation treatment Splenic asthenia and obstruction of dampness gout
Application.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610748422.6A CN106266341A (en) | 2016-08-30 | 2016-08-30 | A kind of Chinese medicine composition treating gout |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610748422.6A CN106266341A (en) | 2016-08-30 | 2016-08-30 | A kind of Chinese medicine composition treating gout |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106266341A true CN106266341A (en) | 2017-01-04 |
Family
ID=57677735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610748422.6A Pending CN106266341A (en) | 2016-08-30 | 2016-08-30 | A kind of Chinese medicine composition treating gout |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106266341A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1970021A (en) * | 2006-11-29 | 2007-05-30 | 林啸 | Chinese medicine for treating gout and preparation method thereof |
| CN101991752A (en) * | 2010-10-20 | 2011-03-30 | 刘思波 | Traditional Chinese medicine formula for treating gout |
| CN102397418A (en) * | 2011-10-09 | 2012-04-04 | 邓华伦 | Chinese herbal medicine preparation for treating gout |
| CN103735697A (en) * | 2013-12-31 | 2014-04-23 | 广西中医药大学 | Chinese medicinal preparation having gout-resisting effect and preparation method thereof |
| CN104887841A (en) * | 2015-07-03 | 2015-09-09 | 李军 | Traditional Chinese medicine preparation for treating gout |
-
2016
- 2016-08-30 CN CN201610748422.6A patent/CN106266341A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1970021A (en) * | 2006-11-29 | 2007-05-30 | 林啸 | Chinese medicine for treating gout and preparation method thereof |
| CN101991752A (en) * | 2010-10-20 | 2011-03-30 | 刘思波 | Traditional Chinese medicine formula for treating gout |
| CN102397418A (en) * | 2011-10-09 | 2012-04-04 | 邓华伦 | Chinese herbal medicine preparation for treating gout |
| CN103735697A (en) * | 2013-12-31 | 2014-04-23 | 广西中医药大学 | Chinese medicinal preparation having gout-resisting effect and preparation method thereof |
| CN104887841A (en) * | 2015-07-03 | 2015-09-09 | 李军 | Traditional Chinese medicine preparation for treating gout |
Non-Patent Citations (1)
| Title |
|---|
| 廖勇敢等: "《内科基础与临床诊疗》", 28 February 2014, 科学技术文献出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106266463B (en) | Traditional Chinese medicine composition for treating hyperuricemia and application thereof | |
| CN100571731C (en) | A kind of Chinese medicine decoction for the treatment of herpes zoster | |
| CN104784624A (en) | Traditional Chinese medicine for treating dyspepsia | |
| CN102274322B (en) | Chinese medicinal preparation for treating eczema | |
| CN104383183A (en) | Medicinal composition for treating non-alcoholic fatty liver | |
| CN101530512B (en) | Medicinal tea for treating rheumatism and rheumatoid disease | |
| CN100586466C (en) | Film coating tablet for treating gynaecologic disease and method for preparing the same | |
| CN104587304B (en) | A kind of medicine for the treatment of Simple Obesity and uses thereof | |
| CN106266341A (en) | A kind of Chinese medicine composition treating gout | |
| CN102836243B (en) | Traditional Chinese medicine for cure of rheumatoid arthritis | |
| CN102335418B (en) | Health-care wine for relieving rheumatoid swelling | |
| CN101129584A (en) | Chinese medicine preparation for treating post partum hypogalactia | |
| CN112516268A (en) | Traditional Chinese medicine composition for treating postpartum disease and preparation method thereof | |
| CN104127753A (en) | Traditional Chinese medicine tea bag for treating gouty arthritis and preparation method thereof | |
| CN104740404A (en) | Traditional Chinese medicine composition for treating lupus erythematosus | |
| CN104367827A (en) | Traditional Chinese medicine for treating spleen-qi deficiency-weakness syndrome type somnolence | |
| CN104740372A (en) | Traditional Chinese medicine composition for treating insomnia | |
| CN102886011A (en) | Traditional Chinese medicine for treating dyspepsia | |
| CN103550622B (en) | A kind of Chinese medicine for stopping postpartum milk secretion | |
| CN106237285A (en) | A kind of Chinese medicine composition treating gout | |
| CN106110081A (en) | A kind of Chinese medicine composition treating gout | |
| CN105106575A (en) | Traditional Chinese medicine composition for treating constipation and preparation method thereof | |
| CN106267093A (en) | A kind of Chinese medicine composition treating weakness of the spleen and stomach and preparation method thereof | |
| CN106177297A (en) | A kind of Chinese medicine composition treating gout | |
| CN103536883B (en) | The Chinese medicine for the treatment of heart kidney qi Yin bivacuity pattern of syndrome spleen fatiguing disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170104 |